Leaders from ANVISA and Mexico’s COFEPRIS ratified the “Rio de Janeiro Declaration” in April 2026. This partnership focuses on regulatory convergence and reducing regional dependence on imported medicines. For advisory firms like BioIntell, this signifies a more harmonized regulatory landscape between Latin America’s two largest economies.
Read more: Brazil and Mexico celebrate health integration and regulatory convergence